Skip to main content

Advertisement

Table 5 Occurrence of all adverse events (AEs) and most frequent on-treatment AEs, ITT population

From: Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

  Number (%) of patients
VI 25 mcg OD (N = 115) SAL 50 mcg BD (N = 116) Placebo (N = 116)
Any AE 55 (48) 48 (41) 47 (41)
Treatment-related AE 2 (2) 4 (3) 5 (4)
AE leading to withdrawal 2 (2) 2 (2) 3 (3)
Any serious AE 1 (<1) 0 (0) 1 (<1)
Any fatal AE 0 (0) 0 (0) 1 (<1)
Most frequent adverse events a    
Nasopharyngitis 9 (8) 7 (6) 12 (10)
Headache 10 (9) 9 (8) 5 (4)
Oropharyngeal pain 6 (5) 2 (2) 7 (6)
Upper respiratory tract infection 2 (2) 2 (2) 8 (7)
  1. a≥5% any treatment group.
  2. BD: twice-daily; ITT: intent-to-treat; OD: once-daily; SAL: salmeterol; VI: vilanterol.